Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Sarcoma 1Dermatologic 1

Conditions

Pancreatic Neoplasms 115Urinary Bladder Neoplasms 56Carcinoma, Non-Small-Cell Lung 53Cholangiocarcinoma 33Biliary Tract Neoplasms 32Neoplasm Metastasis 30Ovarian Neoplasms 29Lymphoma, Large B-Cell, Diffuse 27Breast Neoplasms 25Neoplasms 24Lung Neoplasms 24Carcinoma, Transitional Cell 23Triple Negative Breast Neoplasms 22Nasopharyngeal Carcinoma 21Colorectal Neoplasms 20Non-Muscle Invasive Bladder Neoplasms 19Recurrence 17Fallopian Tube Neoplasms 16Gallbladder Neoplasms 15Sarcoma 13Bile Duct Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Hodgkin Disease 10Lymphoma 9Adenocarcinoma 9Uterine Cervical Neoplasms 8Stomach Neoplasms 7Lymphoma, Non-Hodgkin 7Endometrial Neoplasms 7Nasopharyngeal Neoplasms 6

Interventions

pembrolizumab 5enfortumab vedotin 3Gemcitabine 3dodecyl maltoside 2Sunitinib 2Cisplatin 2zidovudine 5'-monophosphate-mannose-albumin conjugate 1tucatinib 1testosterone 17 beta-cypionate 1temsirolimus 1relatlimab 1palbociclib 1niraparib 1galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20 1cabozantinib 1Valproic Acid 1Urinary Diversion 1Trastuzumab 1Testosterone Propionate 1Standard of Care 1Sirolimus 1Rivaroxaban 1Ringer's acetate 1Radiosurgery 1Radiation Dose Hypofractionation 1Psychiatric Nursing 1Practice Guidelines as Topic 1Physical Therapy Modalities 1Nivolumab 1Multiparametric Magnetic Resonance Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urologic Neoplasms × Gemcitabine × 1 year × Clear all
NCT03093909 2026-05-20

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

M.D. Anderson Cancer Center

Phase 1 Recruiting
44 enrolled
DermatologicGenitourinarySarcoma

Bone Neoplasms, Melanoma, Osteosarcoma, Urologic Neoplasms

NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT03288545 2026-03-24

EV-103

Astellas Pharma Inc

Phase 1/2 Terminated
348 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡